戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 h the patient's clinical capacity to undergo cytoreductive surgery.
2 perioperative outcomes compared with primary cytoreductive surgery.
3 .7 months for patients who received ICT plus cytoreductive surgery.
4 e patient was treated with immunotherapy and cytoreductive surgery.
5 or recurrent ovarian cancer during secondary cytoreductive surgery.
6 spected ovarian cancer, scheduled to undergo cytoreductive surgery.
7 ement of immune responses following ICT plus cytoreductive surgery.
8 apy regimens with or without prior secondary cytoreductive surgery.
9 e either neoadjuvant chemotherapy or primary cytoreductive surgery.
10 18)F-FES PET/CT was performed shortly before cytoreductive surgery.
11 and hemodynamic findings when injected after cytoreductive surgery.
12 e a week either during tumor growth or after cytoreductive surgery.
13 up, disease stage, and timing and outcome of cytoreductive surgery.
14 n with carboplatin and taxane regimens after cytoreductive surgery.
15 s for pathological assessment and for aiding cytoreductive surgery.
16 ase stage and visible residual disease after cytoreductive surgery.
17  were not considered candidates for complete cytoreductive surgery.
18 al has been met, with 43 patients completing cytoreductive surgery, 36 patients undergoing post-ICT b
19 apy and 0.54 (95% CI, 0.36-0.81) for primary cytoreductive surgery (all high certainty).
20              Survival based on the number of cytoreductive surgeries and the free interval between th
21 or with neoadjuvant chemotherapy followed by cytoreductive surgery and adjuvant chemotherapy.
22 fied by a general paradigm of maximally safe cytoreductive surgery and advanced radiation delivery te
23 inical remission after completion of primary cytoreductive surgery and chemotherapy at 6 National Can
24                                              Cytoreductive surgery and heated intraperitoneal chemoth
25 e demonstrates the feasibility and safety of cytoreductive surgery and HIPEC via the laparoscopic rou
26 d perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal c
27    A large proportion of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal c
28       Patients with PM from CRC admitted for cytoreductive surgery and hyperthermic intraperitoneal c
29                                              Cytoreductive surgery and hyperthermic intraperitoneal c
30        Therefore, investigators have applied cytoreductive surgery and hyperthermic perioperative che
31 impact on progression-free survival (PFS) of cytoreductive surgery and international variations in su
32 All patients with colorectal PC referred for cytoreductive surgery and intraperitoneal chemotherapy (
33 ere managed by a treatment regimen that used cytoreductive surgery and intraperitoneal chemotherapy.
34 with PC and synchronous LM who had undergone cytoreductive surgery and LM resection followed by intra
35 ents with OvCa who underwent a diagnostic or cytoreductive surgery and nononcological patients, who u
36 with routine observation (OBS) after primary cytoreductive surgery and platinum-based chemotherapy in
37                     The therapeutic value of cytoreductive surgery and radiation therapy for posterio
38 l carcinomatosis (PC) who underwent complete cytoreductive surgery and resection of LM, followed by i
39                Women who are fit for primary cytoreductive surgery, and with potentially resectable d
40 atients with advanced-stage disease, maximum cytoreductive surgery appears to be beneficial.
41                     The survival benefits of cytoreductive surgery are also applicable to women with
42 years) with abdominopelvic CT before primary cytoreductive surgery available through the Cancer Imagi
43 arian cancer who underwent CT before primary cytoreductive surgery between 1997 and 2004 (mean age, 6
44 ve cure and survival rates involves complete cytoreductive surgery (CCRS) and hyperthermic intraperit
45                           PURPOSE OF REVIEW: Cytoreductive surgery combined with hyperthermic intrape
46                              The efficacy of cytoreductive surgery combined with perioperative intrap
47           The current evidence suggests that cytoreductive surgery combined with perioperative intrap
48 pectively collected data on patients who had cytoreductive surgery (CRS) and HIPEC in a single instit
49 idity (MM) and failure-to-rescue (FTR) after cytoreductive surgery (CRS) and hyperthermic intraperito
50 valuate outcome and long-term survival after cytoreductive surgery (CRS) and hyperthermic intraperito
51 cer may be treated with a curative intent by cytoreductive surgery (CRS) and hyperthermic intraperito
52                                              Cytoreductive surgery (CRS) and hyperthermic intraperito
53                                              Cytoreductive surgery (CRS) and hyperthermic intraperito
54 zed trial demonstrated a survival benefit of cytoreductive surgery (CRS) and intraperitoneal chemothe
55 etastases of colorectal cancer, treated with cytoreductive surgery (CRS) and resulting in a pathologi
56 ould impact the failure-to-rescue rate after cytoreductive surgery (CRS) for peritoneal carcinomatosi
57                                              Cytoreductive surgery (CRS) has emerged as a survival-ex
58 aperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improved recurrence-free and
59                                              Cytoreductive surgery (CRS) is one of the most complex o
60                                              Cytoreductive surgery (CRS) with hyperthermic intraperit
61                                              Cytoreductive surgery (CRS) yields promising results, bu
62 varian cancer who are ineligible for primary cytoreductive surgery (CRS).
63 t setting of patients who underwent complete cytoreductive surgery(CRS) for recurrent adult type gran
64 as management strategies, including complete cytoreductive surgery embedded in perioperative systemic
65 he expansion of treatment options, including cytoreductive surgery followed by chemotherapy with hype
66 gical malignancy that is commonly treated by cytoreductive surgery followed by cisplatin treatment.
67 e was randomly assigned to undergo secondary cytoreductive surgery followed by three more cycles of c
68 fic immunotherapy should be considered after cytoreductive surgery for advanced melanoma.
69                                  Death after cytoreductive surgery for advanced-stage ovarian cancer
70 resh human tissue taken from patients during cytoreductive surgery for peritoneal metastasis of colon
71 e of HIPEC with carboplatin during secondary cytoreductive surgery for platinum-sensitive recurrent o
72                                     Interval cytoreductive surgery has been shown to confer a surviva
73 mic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have been shown to benefit selecte
74   Using fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection
75 perthermic intraperitoneal chemotherapy with cytoreductive surgery (HIPEC + CS).
76                                     Interval cytoreductive surgery (ICS) should be performed after <=
77 e availability of retroperitoneal staging or cytoreductive surgery if necessary.
78 ospective study of CT images obtained before cytoreductive surgery in 46 women with HGSOC, whose tumo
79 ighted the feasibility of combining ICT with cytoreductive surgery in a metastatic setting and demons
80         A new treatment strategy starts with cytoreductive surgery in an attempt to remove all visibl
81            Despite continuing debates around cytoreductive surgery in malignant gliomas, there is bro
82                                 However, how cytoreductive surgery in the metastatic setting modulate
83  Immune-monitoring studies demonstrated that cytoreductive surgery increased antigen-presenting dendr
84 troy small residual mucinous tumour nodules, cytoreductive surgery is combined with intraperitoneal c
85                             However, primary cytoreductive surgery is preferred if there is a high li
86                           As such, extensive cytoreductive surgery is required prior to IPC.
87 and tertile of program mean annual volume of cytoreductive surgery (&lt;12.0, 12.0-23.9, or >=24.0 cases
88  in metastatic melanoma tumors obtained from cytoreductive surgery of AJCC stage IV melanoma patients
89 r; however, a subset of patients who undergo cytoreductive surgery of distant metastases survive for
90 ree different ICT-containing strategies with cytoreductive surgery or biopsy for patients with metast
91                  Patients receiving ICT with cytoreductive surgery or biopsy, did not experience addi
92 rent disease may be eligible for a secondary cytoreductive surgery or may require a surgical interven
93 sex (P < .001), age </= 65 years (P = .005), cytoreductive surgery (P < .001), and epithelioid histol
94 ostic laparoscopy can prevent futile primary cytoreductive surgery (PCS) by identifying patients with
95 mains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy
96 nt chemotherapy (NACT) compared with primary cytoreductive surgery (PCS).
97 randomly assigned to receive either interval cytoreductive surgery performed using MIS or laparotomy.
98 nt of advanced-stage ovarian cancer includes cytoreductive surgery, platinum-based chemotherapy, and
99 ecurrence develops are candidates for repeat cytoreductive surgery plus intraperitoneal chemotherapy
100                                              Cytoreductive surgery plus systemic chemotherapy may be
101            There is no known cure for PM and cytoreductive surgery remains controversial.
102 e ovarian cancer may be treated with primary cytoreductive surgery (removal of all visible cancer in
103          The impact on survival of secondary cytoreductive surgery requires more investigation.
104 he roles of primary, interval, and secondary cytoreductive surgeries; second-look procedures; and pal
105  We evaluated the effect of adding secondary cytoreductive surgery to postoperative chemotherapy on p
106 red to be maximal, the addition of secondary cytoreductive surgery to postoperative chemotherapy with
107                                      Primary cytoreductive surgery was associated with improved survi
108 h advanced ovarian carcinoma in whom primary cytoreductive surgery was considered to be maximal, the
109 tum, or peritoneal metastasis that underwent cytoreductive surgery were all excluded.
110      Histology, grade, stage, and success of cytoreductive surgery were similar for hereditary and sp
111 apy alone has recently been demonstrated for cytoreductive surgery when combined with intraoperative
112 fluence the surgeon's decision on performing cytoreductive surgery, which may be followed by intraper
113 ns were obtained from PM patients undergoing cytoreductive surgery with HIPEC.
114 5% CI, 18 to 32) in the group that underwent cytoreductive surgery with HIPEC.
115 e been made thanks to new techniques such as cytoreductive surgery with hyperthermic intraperitoneal
116                                              Cytoreductive surgery with hyperthermic intraperitoneal
117 pre-existing database of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal
118                                       During cytoreductive surgery with hyperthermic intraperitoneal
119                            Patient underwent cytoreductive surgery with residual disease and a pathol

 
Page Top